

ORIGINAL ARTICLE

Subtype selective fluorescent ligands based on ICI 118,551 to study the human β_2 -adrenoceptor in CRISPR/Cas9 genome-edited HEK293T cells at low expression levels

Joëlle Goulding^{1,2}  | Sarah J. Mistry^{2,3}  | Mark Soave^{1,2}  | Jeanette Woolard^{1,2}  |
 Stephen J. Briddon^{1,2} | Carl W. White^{1,2,4,5}  | Barrie Kellam^{2,3}  | Stephen J. Hill^{1,2} 

¹Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, UK

²Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, UK

³School of Pharmacy, University of Nottingham, Nottingham, UK

⁴Harry Perkins Institute of Medical Research and Centre for Medical Research, University of Western Australia, QEII Medical Centre, Nedlands, Western Australia, Australia

⁵Australian Research Council Centre for Personalised Therapeutics Technologies, Australia

Correspondence

Stephen J. Hill and Barrie Kellam, Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, UK.

Email: Stephen.hill@nottingham.ac.uk (S. J. H.); barrie.kellam@nottingham.ac.uk (B. K.)

Funding information

Medical Research Council, Grant/Award Number: MR/N020081/1

Abstract

Fluorescent ligand technologies have proved to be powerful tools to improve our understanding of ligand-receptor interactions. Here we have characterized a small focused library of nine fluorescent ligands based on the highly selective β_2 -adrenoceptor (β_2 AR) antagonist ICI 118,551. The majority of fluorescent ICI 118,551 analogs had good affinity for the β_2 AR ($pK_D > 7.0$) with good selectivity over the β_1 AR ($pK_D < 6.0$). The most potent and selective ligands being **8c** (ICI 118,551-Gly-Ala-BODIPY-FL-X; β_2 AR pK_D 7.48), **9c** (ICI 118,551- β Ala- β Ala-BODIPY-FL-X; β_2 AR pK_D 7.48), **12a** (ICI 118,551-PEG-BODIPY-X-630/650; β_2 AR pK_D 7.56), and **12b** (ICI 118,551-PEG-BODIPY-FL; β_2 AR pK_D 7.42). **9a** (ICI 118,551- β Ala- β Ala-BODIPY-X-630/650) had the highest affinity at recombinant β_2 ARs (pK_D 7.57), but also exhibited significant binding affinity to the β_1 AR (pK_D 6.69). Nevertheless, among the red fluorescent ligands, **9a** had the best imaging characteristics in recombinant HEK293 T cells and labeling was mostly confined to the cell surface. In contrast, **12a** showed the highest propensity to label intracellular β_2 ARs in HEK293 T cell expressing exogenous β_2 ARs. This suggests that a combination of the polyethylene glycol (PEG) linker and the BODIPY-X-630/650 makes this ICI 118,551 derivative particularly susceptible to crossing the cell membrane to access the intracellular β_2 ARs. We have also used these ligands in combination with CRISPR/Cas9 genome-edited HEK293 T cells to undertake for the first time real-time ligand binding to native HEK293 T β_2 ARs at low native receptor expression levels. These studies provided quantitative data on ligand-binding characteristics but also allowed real-time visualization of the ligand-binding interactions in genome-edited cells using NanoBRET luminescence imaging.

KEYWORDS

CRISPR/Cas9 genome editing, fluorescent ligands, ICI 118,551, ligand binding, NanoBRET, β_2 -adrenoceptors

Joëlle Goulding and Sarah J. Mistry are contributed equally to this work.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. *Pharmacology Research & Perspectives* published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.

1 | INTRODUCTION

Beta-adrenoceptors (β ARs) are Class A G protein-coupled receptors (GPCRs) which have been successfully targeted for the treatment of cardiovascular and respiratory disorders.^{1,2} There are three receptor subtypes, β_1 AR, β_2 AR, and β_3 AR, which display tissue-specific localization and functionality.³⁻⁵ All three subtypes are found in the heart, with the β_1 AR being the most abundant and is able to regulate heart rate and contractile force.⁶ β_2 ARs can couple to both G_{as} and G_{ai} heterotrimeric G proteins.⁷⁻⁹ They are found within the smooth muscle of the airways and can be targeted to relieve symptoms of respiratory disorders, such as asthma and chronic obstructive pulmonary disease.^{2,9} The β_3 AR has limited expression, chiefly in adipose tissue and the bladder, but can also be found at low expression levels in the heart.¹⁰⁻¹²

The β_2 AR is a commonly used model for Class A GPCRs within research. This has been facilitated by the myriad of tools with which to study its role and function, including numerous published crystal structures showing the receptor in an inactive state bound to the negative allosteric nanobody 60,¹³ as well as the agonist,¹⁴⁻¹⁶ inverse agonist,¹⁷ and G protein-bound states.¹⁵ Traditionally, ligand-binding parameters have been determined using radiolabeled ligands as the pharmacological probe. However, these approaches are not readily applicable to the study of receptor properties in living cells and in real time.

Recent advances in fluorescent ligand design have allowed the development of live-cell real-time ligand-receptor binding assays.¹⁸⁻²⁰ Fluorescent ligands can inform on receptor localization, expression level, ligand affinity, receptor specificity, and ligand-binding kinetics through the use of imaging techniques, and those based on resonance energy transfer.¹⁸⁻²⁴ The composition of the fluorescent ligand (the orthosteric binding moiety, linker and fluorophore) can exert significant effects on its utility as a probe, including modulating the selectivity profile of the probe and changing its photochemical properties, which affects its use for confocal microscopy.²⁵ To date, there are no highly selective fluorescent probes available to study the β_2 AR, and many existing β AR fluorescent ligands have very limited β_2 AR/ β_1 AR selectivity.^{26,27}

Fusion of a luciferase to a receptor of interest has allowed a range of biological effects to be investigated using bioluminescence resonance energy transfer (BRET).²⁸ We have recently shown how fluorescent ligands can be used in combination with nanoluciferase to provide an exquisitely sensitive NanoBRET ligand-binding assay.^{18,21,29} Until recently, however, the use of NanoBRET to investigate ligand-binding properties required the exogenous expression of the nanoluciferase-tagged GPCR of interest, and this can affect how receptors interact and signal. To maintain the normal cellular context, we have previously used CRISPR/Cas9-mediated homology-directed repair to insert luminescent tags into the endogenous genome.³⁰⁻³² Here, we describe novel and highly selective fluorescent ligands based on the β_2 AR selective antagonist ICI 118,551³³ and linked to different fluorophores with a variety of linkers. We characterize these ligands in terms of β AR affinity and selectivity

using a NanoBRET proximity-based binding assay²⁹ and examine their imaging properties via confocal microscopy. We also use them to demonstrate fluorescent ligand binding to genome-edited β_2 ARs at low native levels of receptor expression in HEK293 T cells.

2 | MATERIALS AND METHODS

2.1 | Materials

FuGENE and furimazine were obtained from Promega. SNAP-Surface®, Alexa Fluor® 488 and Alexa Fluor 647 were obtained from New England Biolabs. ³H-CGP12177 and MicroScint 20 were from Perkin Elmer. All other chemicals were from Sigma-Aldrich. Nunc™ Lab-Tek™ chambered coverglass (155361) was obtained from Thermo Fisher Scientific. 96-well white clear-bottomed plates and 35 mm Cellview 4-quadrant culture dishes were from Greiner Bio-One.

2.2 | Chemistry

Chemicals and solvents of analytical and HPLC grade were purchased from commercial suppliers and used without further purification. BODIPY-630/650-X-SE, BODIPY-FL-X-SE, and BODIPY-FL-SE were purchased from Molecular Probes (Thermo Fisher Scientific). All reactions were carried out at ambient temperature unless otherwise stated. Reactions were monitored by thin-layer chromatography on commercially available silica pre-coated aluminum-backed plates (Merck Kieselgel 60 F254). Visualization was under UV light (254 nm and 366 nm), followed by staining with ninhydrin or KMnO₄ dips. Flash column chromatography was performed using silica gel 60, 230–400 mesh particle size (Sigma-Aldrich). NMR spectra were recorded on a Bruker-AV 400. ¹H spectra were recorded at 400.13 Hz and ¹³C NMR spectra at 101.62 Hz. All ¹³C NMR are ¹H broadband decoupled. Solvents used for NMR analysis (reference peaks listed) were CDCl₃ supplied by Cambridge Isotope Laboratories Inc., ($\delta_{\text{H}} = 7.26$ ppm, $\delta_{\text{C}} = 77.16$) and CD₃OD supplied by VWR ($\delta_{\text{H}} = 3.31$ ppm and $\delta_{\text{C}} = 49.00$). Chemical shifts (δ) are recorded in parts per million (ppm) and coupling constants are recorded in Hz. The following abbreviations are used to describe signal shapes and multiplicities; singlet (s), doublet (d), triplet (t), quadruplet (q), broad (br), dd (doublet of doublets), ddd (double doublet of doublets), dtd (double triplet of doublets), and multiplet (m). Spectra were assigned using appropriate COSY and HSQC experiments. Processing of the NMR data was carried out using the NMR software Topspin 3.0. LC-MS spectra were recorded on a Shimadzu UFLCXR system coupled to an Applied Biosystems API2000 and visualized at 254 nm (channel 1) and 220 nm (channel 2). LC-MS was carried out using a Phenomenex Gemini-NX C18 110A, column 50 mm \times 2 mm \times 3 μ m at a flow rate of 0.5 ml/min over a 5 min period. All high-resolution mass spectra (HRMS) were recorded on a Bruker microTOF mass spectrometer using MS electrospray ionization operating in

positive ion mode. RP-HPLC was performed on a Waters 515 LC system and monitored using a Waters 996 photodiode array detector at wavelengths between 190 and 800 nm. Spectra were analyzed using Millennium 32 software. Semi-preparative HPLC was performed using YMC-Pack C8 column (150 mm \times 10 mm \times 5 μ m) at a flow rate of 5.0 ml/min using a gradient method of 40–95% B over 15 minutes (solvent A = 0.01% formic acid in H₂O, solvent B = 0.01% formic acid in CH₃CN (method A)) or 40–75% B over 10 minutes (solvent A = 0.01% formic acid in H₂O, solvent B = 0.01% formic acid in CH₃CN (method B)). Analytical RP-HPLC was performed using a YMC-Pack C8 column (150 mm \times 4.6 mm \times 5 μ m) at a flow rate of 1.0 ml/min. Final products were one single peak and >95% pure. The retention time of the final product is reported using a gradient method of 5–95% solvent B in solvent A over 25 minutes (solvent A = 0.01% formic acid in H₂O, solvent B = 0.01% formic acid in CH₃CN).

Full experimental detail for the synthesis of fluorescent ligands can be found in the Data S1.

2.3 | Cell lines

HEK cell lines were maintained in Dulbecco's Modified Eagle Medium (DMEM; Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich) at 37°C in 5% CO₂. The NLuc- β_2 AR stable cell line was obtained from Promega. The NLuc- β_1 AR³⁴ was transiently expressed in HEK293 GloSensor cells (Promega) using FuGENE (Promega), according to the manufacturer's instructions. Briefly, HEK293 GloSensor cells (120,000/well) were plated on a clear 6-well plate in 500 μ l complete medium. Twenty-four hours after seeding, the cells were transiently transfected with 1 μ g/well NLuc- β_1 AR in a 1:3 ratio of DNA:FuGENE and incubated at 37°C in 5% CO₂;air for a further 24 hours before being used for NanoBRET experiments. The SNAP- β_2 AR clonal stable cell line was a gift from Dr Karolina Gherbi (University of Nottingham). CRISPR/Cas9 genome engineering of the N-terminal region of the β_2 AR genomic locus in HEK293 T cells to incorporate either a SNAP- or an NLuc-tag was performed as described previously.^{32,35} Chinese Ovary Hamster (CHO) cell lines stably expressing either the β_1 AR or β_2 AR were maintained in DMEM/F12 supplemented with 10% FBS and 2 mM L-glutamine at 37°C in 5% CO₂. The CHO cell lines were a gift from Prof. Jillian Baker (University of Nottingham).

2.4 | NanoBRET binding assay

Saturation and competition binding assays were performed as previously described.²⁹ Cells were seeded in 96-well white clear-bottomed Greiner plates pre-treated with 10 μ g/ml poly-D-lysine (Sigma-Aldrich) at a density of 35,000 cells per well in DMEM supplemented with 10% FBS. The following day, the media were removed and cells were incubated with the fluorescent ICI 118,551 derivative in the presence or absence of 10 μ M propranolol (saturation binding

assays) or competing ligand in the presence of 10 nM fluorescent ligand (competition binding assays) in HEPES-buffered saline solution (HBSS; 145 mM NaCl, 5 mM KCl, 1.3 mM CaCl₂, 1 mM MgSO₄, 10 mM HEPES, 2 mM sodium pyruvate, 1.5 mM NaHCO₃, and 10 mM D-glucose, pH 7.45) with 0.1% bovine serum albumin for 1 hr at 37°C. The NanoLuc substrate, furimazine (Promega), was then added to each well (10 μ M final concentration) and the plate was incubated for 15 min in the dark at 37°C. The resulting BRET was measured using a PHERAstar FS plate reader (BMG Labtech) at room temperature. For each well filtered light emissions at 460 nm (80 nm bandpass) and >610 nm (longpass) for the BODIPY 630/650 ligands, and at 475 nm (30 nm bandpass) and 535 nm (30 nm bandpass) for the BODIPY-FL and BODIPY-X-FL ligands were simultaneously measured. BRET ratios were calculated by dividing the longer wavelength emission by the 460 nm or 475 nm emission, respectively.

2.5 | Radioligand binding

Competition binding assays were performed as previously described³⁶ using CHO- β_1 AR or CHO- β_2 AR cell lines. Briefly, cells, plated in 96-well white clear-bottomed Greiner plates, were incubated for 2 h at 37°C in 5% CO₂ in the presence of 0.8–1.2 nM ³H-CGP 12177 (Perkin Elmer) and competing ligands (10 pM – 10 μ M) in serum-free medium. Non-specific binding was assessed by incubating in the presence of 10 μ M propranolol. Cells were washed twice in PBS before addition of 200 μ l MicroScint 20 (PerkinElmer), then incubated in the dark overnight before being read on a TopCount Microplate Scintillation Counter (Packard Instrument, CT).

2.6 | Confocal imaging

SNAP- β_2 AR cells were seeded onto poly-D-lysine-coated (10 μ g/ml) 8-well Nunc™ Lab-Tek™ chambered coverglass (No. 1.0 borosilicate glass bottom) in DMEM supplemented with 10% FBS at a density of 10–15,000 cells per well 2 days prior to experiment. On the day of the experiment, media were replaced with labeling media which contained SNAP-Surface® Alexa Fluor® 488 or 647 (New England Biolabs) at a final concentration of 0.5 μ M (for 30 min at 37°C). Cells were then washed in warm HBSS before a final addition of 200 μ l of HBSS per well.

Cells were imaged on a Zeiss LSM880 with a Zeiss Axio Observer Z1 stand (Carl Zeiss) with a 40 \times C-apochromat NA1.2 water immersion objective. Excitation was via 488 nm Argon and 633 nm helium-neon laser lines with a 488/561/633 multi-beam splitter and emission collected using a 493–628 bandpass or 638–737 bandpass. The pinhole was set at 1 Airy unit for the longer wavelength and laser power and gain and offset settings kept constant within experiment to allow comparison. Cells were imaged live at 24°C following a 30 min pre-incubation at 37°C in the presence of fluorescent ligand (100 nM) following a 30 min pre-incubation at 37°C in the presence or absence of 10 μ M

propranolol. Equatorial plane images were made and four images captured per condition per experiment using ZEN 2012 software (Carl Zeiss).

2.7 | NanoBRET imaging

Cells were seeded onto 35 mm Cellview 4-quadrant culture dishes (Greiner Bio-one), which have a 10 mm glass coverslip bottom, in DMEM supplemented with 10% FBS at a density of 100,000 cells per quadrant 2 days prior to experiment. On the day of the experiment, media were replaced with HBSS in the presence or absence of fluorescent ligand (100 nM) and/or propranolol (10 μ M) and incubated on the microscope for 30 mins at 37°C before imaging. Bioluminescence and NanoBRET imaging were performed on an Olympus LuminoView 200 microscope with a 60x NA1.42 oil immersion objective with a 0.5x tube lens, following addition of furimazine (5 μ M) (Promega). Images were captured by a C9100-23B IMAGE EMX2 camera (Hamamatsu, Japan) with gain set at 200 for all channels. Filtered bioluminescence was captured using a 438/24 nm band-pass filter (5 s – 1 min exposure time dependent on expression level), BRET in the presence of **9a** was captured using a 650/50 nm band-pass filter and in the presence of **12c** using a 509/22 nm band-pass filter. For the NLuc- β_2 AR stable cell line, exposure times were set at 10 s (**12a, 9a**) or 20 s (**9c**) for filtered bioluminescence and 1 min (**9a, 12a**) or 20 s (**9c**) for BRET, and for the HEK293 T cells expressing NLuc- β_2 AR under endogenous promotion, exposure times were set at 1 min for filtered bioluminescence and 4 min for BRET. Raw intensity values were determined for 3–5 regions of interest per experiment per condition and the BRET ratio was calculated by dividing the raw intensity recorded from the BRET capture by the filtered bioluminescence capture. Corrected BRET ratios were determined by subtracting the BRET ratio determined from a control quadrant (HBSS alone). A minimum of three separate experiments were performed for each condition.

2.8 | Data analysis

Data were analyzed using Prism 7.4 software (GraphPad, San Diego, USA). Saturation NanoBRET curves were fitted simultaneously for total (fluorescent ICI 118,551 ligand) and non-specific binding (in the presence of 10 μ M propranolol) using the following equation:

$$\text{Total binding} = \frac{B_{\max} \times [B]}{[B] + K_D} + m \times B + c$$

where B_{\max} is the maximal specific binding, [B] is the concentration of the fluorescent ligand (nM), K_D is the equilibrium dissociation constant (nM), m is the slope of the non-specific binding component, and c is the y-axis intercept.

The affinities of ligands at the β_2 -AR were calculated from competition binding data with a one-site sigmoidal response curve given by the following equation:

$$\% \text{ Inhibition of specific binding} = \frac{(100 \times [A]^n)}{([A]^n + IC_{50}^n)}$$

where [A] is the concentration of unlabeled ligand, n is the Hill coefficient, and IC_{50} is the concentration of ligand required to inhibit 50% of fluorescent ligand. The IC_{50} values were then used to calculate the K_i values using the Cheng-Prusoff equation:

$$K_i = \frac{IC_{50}}{1 + \frac{[L]}{K_D}}$$

where [L] is the concentration of fluorescent ICI 118,551 ligand in nM, and K_D is the dissociation constant of either the fluorescent ligand (NanoBRET assay) or 3 H-CGP 12177 (radioligand assay) in nM. The K_D of 3H-CGP 12177 has previously been reported for the CHO cell lines employed here³⁶ as 0.42 nM (β_1) and 0.17 nM (β_2).

Bioluminescence and NanoBRET images were analyzed using ImageJ (<http://rsb.info.nih.gov/ij>; NIH, USA) and the Time Series Analyzer version 3.0 (<https://imagej.nih.gov/ij/plugins/time-series.html>).³⁷

2.9 | Nomenclature of targets and ligands


Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY,³⁸ and are permanently archived in the Concise Guide to PHARMACOLOGY 2019/20.³⁹

3 | RESULTS

3.1 | Synthesis of ICI 118,551 fluorescent ligands

The highly β_2 AR-selective antagonist ICI 118,551 was used as the starting point for the development of selective β_2 AR fluorescent ligands. The crystal structure of the human β_2 AR bound to this ligand has been previously solved (PDB 3NY8⁴⁰;) and this aided identification of an appropriate attachment point on ICI 118,551 for a fluorophore via different linkers. In parallel to our own previous successes in designing and synthesizing fluorescent β -adrenoceptor ligands,^{27,41} the crystal structure suggested the alkylated amine as an ideal tether-point, while ensuring retention of its basic pharmacophoric properties. We therefore generated a small focused library of nine ligands based on combinations of three linkers and three fluorophores (Figure 1), since previous work had demonstrated that both moieties can have a significant effect on affinity and imaging

FIGURE 1 Structures of fluorescent ICI 118,551 derivatives



properties.^{25,42,43} The linkers connecting the ICI 118,551 orthostere to the fluorophore consisted of a polyethylene glycol (PEG) chain (**12a-c**), a Gly-Ala dipeptide linker (**8a-c**), or a β -Ala- β -Ala (**9a-c**) linker (Figure 1), and were chosen based on earlier experience and the success of PEG and β -Ala- β -Ala linkers in previous work with fluorescent propranolol derivatives [27, 41]. To allow spectral choice for these tools, BODIPY-630/650-X (red-emitting), BODIPY-FL (green-emitting), or BODIPY-FL-X (green-emitting) fluorophores were utilized. The synthetic approach to the generation of these fluorescent ligands is detailed in Data S1 and Figure S1.

3.2 | Pharmacological characterization of fluorescent ICI 118,551 analogs

Initial NanoBRET saturation binding experiments²⁹ were performed with all nine fluorescent ligands at the NLuc- β_2 AR and NLuc- β_1 AR receptors to determine their affinity (K_D) for each receptor and thereby determine their β_2/β_1 AR selectivity. The NanoBRET binding assay has been successfully implemented for ligand-binding studies at the NLuc- β_1 AR³⁴ and NLuc- β_2 AR^{29,41} using propranolol-based fluorescent probes. An established stable HEK293 T cell line expressing the NLuc- β_2 AR was used for the evaluation of ligand-binding properties at the β_2 AR, whereas β_1 AR affinities were determined in HEK293 T cells transiently transfected to express NLuc- β_1 AR.

All nine fluorescent ligands displayed saturable binding at the NLuc- β_2 AR (Figure 2; Table 1). Minimal non-specific binding was observed following co-incubation with 10 μ M propranolol. The majority of the fluorescent ligands displayed minimal specific binding at the NLuc- β_1 AR up to the highest concentration used (500 nM) in this assay (Figure 2; Table 1). Only one compound (**9a**) displayed significant specific binding ($p < 0.05$; two-way ANOVA) to the NLuc- β_1 AR over this concentration range (pK_D 6.65 ± 0.15 , $n = 6$; Figure 2F). The estimated affinity for **9a** at the NLuc- β_1 AR was, however, an order of magnitude lower than that measured at the NLuc- β_2 AR (pK_D 7.57 ± 0.06 , $n = 5$; Table 1).

Two fluorescent ligands with different spectral properties were selected for further characterization. **9c** (ICI 118,551-Gly-Ala-BODIPY-FL-X; green ligand) and **12a** (ICI 118,551-PEG-BODIPY-630/650-X; red ligand) were selected due to their β_2 AR/ β_1 AR selectivity, affinity at the NLuc- β_2 AR, and their different fluorophores, respectively. The specific binding of both ligands was inhibited by a panel of β AR ligands (Figure 3). The resulting affinities of these unlabeled ligands at the NLuc- β_2 AR were in

good agreement with literature values previously determined with radioligand binding at the untagged β_2 AR (Table 2).^{36,44}

In order to check that the NLuc tag did not influence ligand binding to each β AR subtype, we performed competition radioligand binding studies in CHO cells stably expressing the wild-type β_1 AR or β_2 AR subtype. CHO cells were chosen since they do not endogenously express β ARs. β_2 AR/ β_1 AR selectivity was maintained with **9c** and **12a** displaying comparable affinities to those seen in the NanoBRET assays (Table 3; Figure S2).

3.3 | Confocal imaging of β_2 AR in transfected HEK293 T cells

To assess the imaging properties of two ICI 118,551 derivatives containing the green BODIPY-FL-X fluorophore (**9c**, **8c**) and two containing the red BODIPY-X-630/650 fluorophore (**9a**, **9c**), confocal microscopy was carried out on an HEK293 T cell line stably expressing the SNAP- β_2 AR. The cells were labeled with SNAP surface Alexa Fluor 647 or 488, depending on the fluorescent ligand under investigation. Equatorial plane images following 30-minute pre-incubation of the cells with fluorescent ligand (100 nM) at 37°C displayed clear membrane localization of the ligand which matched that observed with the SNAP-labeled receptor (Figure 4). Some SNAP-labeled receptor was also observed within the cytosol of cells indicating the presence of internalized receptor. The SNAP label is cell-impermeant and as such any label internal to the cell must have been actively internalized alongside the receptor.

All four fluorescent ICI 118,551 derivatives were detected to differing extents inside cells matching the distribution of β_2 ARs seen with the SNAP dye. This suggested that the fluorescent ligand had either been internalized along with receptor or is able to cross the cell membrane independently and then bind to intracellular receptors. The presence of internalized SNAP- β_2 AR associated with fluorescent ligand was most apparent with **12a** (Figure 4G), which suggests that a combination of the PEG linker and the BODIPY-X-630/650 makes this ICI 118,551 derivative particularly susceptible to crossing the cell membrane to the intracellular regions of the cell (Figure 4G).

No wash steps were performed in these experiments, but free fluorescent ligand was not detected within the imaging buffer. This is a property common to the BODIPY fluorophores, which appear to have a greater quantum yield when bound to GPCRs in a lipid environment.⁴⁵ To establish the specific binding of **8c**, **9a**, **9c**, and **12a**


β_2 AR

FIGURE 2 NanoBRET saturation binding curves of fluorescent ICI 118,551 derivatives in HEK293 T cells exogenously expressing NLuc- β_2 AR or NLuc- β_1 AR. Cells were incubated with 9c (A,D), 12a (B,E), and 9a (C,F) binding to HEK293 T cells expressing NLuc- β_2 AR (A-C) or NLuc- β_1 AR (D-F). Data were obtained in the absence (filled circles) and presence (open circles) of 10 μ M propranolol. Data are mean \pm S.E.M obtained in six (A), five (B, C, D, F), or four (E) separate experiments. Two-way ANOVA (with treatments and concentrations as variables) was used to test for differences between total and non-specific binding for each fluorescent ligand. Significant differences ($P < .05$) were obtained for the data in A, B, C, and F

| No | Fluorescent ICI 118,551 analog | β_2 AR pK _D | n | β_1 AR pK _D | n |
|-----|--|------------------------------|---|------------------------------|---|
| 8a | ICI 118,551-Gly-Ala-BODIPY-X-630/650 | 7.48 \pm 0.08 | 6 | NSB | 5 |
| 8b | ICI 118,551-Gly-Ala-BODIPY-FL | 6.31 \pm 0.11 | 4 | NSB | 5 |
| 8c | ICI 118,551-Gly-Ala-BODIPY-FL-X | 7.48 \pm 0.10 | 6 | NSB | 5 |
| 9a | ICI 118,551- β Ala- β Ala-BODIPY-X-630/650 | 7.57 \pm 0.06 | 5 | 6.69 \pm 0.15 | 6 |
| 9b | ICI 118,551- β Ala- β Ala-BODIPY-FL | 7.07 \pm 0.10 | 5 | NSB | 5 |
| 9c | ICI 118,551- β Ala- β Ala-BODIPY-FL-X | 7.48 \pm 0.08 | 5 | NSB | 5 |
| 12a | ICI 118,551-PEG-BODIPY-X-630/650 | 7.56 \pm 0.08 | 5 | NSB | 5 |
| 12b | ICI 118,551-PEG-BODIPY-FL | 7.42 \pm 0.18 | 4 | NSB | 5 |
| 12c | ICI 118,551-PEG-BODIPY-FL-X | 7.25 \pm 0.04 | 5 | NSB | 5 |

TABLE 1 Dissociation constants, pK_D, of nine fluorescent ICI 118,551 ligands for the NLuc- β_2 AR and NLuc- β_1 AR determined from NanoBRET saturation binding curves. Data are mean pK_D \pm S.E.M for n separate experiments. NSB; no specific binding detected at the highest concentration of fluorescent ligand used (500 nM)

to the SNAP- β_2 AR, cells were pre-incubated with 10 μ M propranolol for 30 minutes prior to addition of fluorescent ligand. A clear reduction in membrane fluorescence of all four fluorescent ligands

was observed, indicating that the majority of fluorescence denotes specific binding to the SNAP- β_2 AR (Figure 4; Figure S3). This was also true of the cytosolic receptor binding.




FIGURE 3 NanoBRET competition binding in HEK293 T cells exogenously expressing NLuc- β_2 AR. Cells were incubated with 10 nM 9c (A) or 12a (B) in the absence or presence of competing ligands. Data are mean \pm S.E.M. from five or six independent experiments. The actual number of repeat experiments is provided in Table 2

TABLE 2 Dissociation constants, pK_i , of unlabeled compounds obtained from inhibition of the specific binding of 10 nM 9c or 12a to NLuc- β_2 AR. Data are mean $pK_i \pm$ S.E.M from n separate experiments, where each experiment was performed in triplicate

| | (pK_i) | | | |
|-------------|-----------------|-----|-----------------|-----|
| | 9c | n | 12a | n |
| Propranolol | 9.48 \pm 0.35 | 5 | 9.55 \pm 0.32 | 6 |
| ICI 118,551 | 8.95 \pm 0.26 | 6 | 8.98 \pm 0.21 | 6 |
| CGP 20712A | 6.03 \pm 0.16 | 5 | 6.19 \pm 0.27 | 6 |
| Salmeterol | 8.45 \pm 0.31 | 6 | 9.01 \pm 0.36 | 5 |

3.4 | NanoBRET imaging of the binding of 9a, 9c, and 12a to transfected HEK293 T cells expressing recombinant NLuc- β_2 ARs

To evaluate whether the proximity requirements (<10 nm) of NanoBRET allowed good localization of fluorescent ICI 118,551

TABLE 3 Dissociation constants, pK_i , determined from inhibition of specific binding of 3 H-CGP 12177 to β_2 AR or β_1 AR expressed in CHO cells. ND, Not determined; no inhibition of specific binding greater than 50% was observed at the maximal concentration tested (1 μ M for 9c and 12a; 10 μ M for CGP 20712A). Data are mean $pK_i \pm$ S.E.M from n separate experiments, each performed in triplicate

| | (pK_i) | | | |
|-------------|-----------------|-----|-----------------|-----|
| | β_2 AR | n | β_1 AR | n |
| 9c | 8.29 \pm 0.17 | 5 | ND | 6 |
| 12a | 7.64 \pm 0.21 | 5 | ND | 6 |
| ICI 118,551 | 8.76 \pm 0.22 | 5 | 6.44 \pm 0.14 | 6 |
| CGP 20712A | ND | 5 | 8.37 \pm 0.18 | 6 |

analog binding to both cell surface NLuc- β_2 ARs and intracellular NLuc- β_2 ARs in transfected HEK293 T cells, we also undertook bioluminescence imaging using an Olympus LV200 microscope (Figure 5). Filtered luminescence from NLuc- β_2 ARs was captured using a 428/24 band-pass filter to allow blue light largely emitted from the N-terminal nanoluciferase to be monitored. BRET-emitted light from the red BODIPY-X-630/650 fluorophore attached to 9a and 12a was captured using 650/50 nm band-pass filter and the BRET-emitted light from the green BODIPY-X-FL fluorophore attached to 9c was collected using a 509/22 nm band-pass filter (Figure 5). All three fluorescent ICI 118,551 ligands showed clear NanoBRET binding to the NLuc- β_2 ARs that was clearly displaceable by 10 μ M propranolol (Figure 5). The extent of ligand binding in the presence of 10 μ M propranolol appeared higher for the green ligand (9c; Figure 5), but this is partly due to the bleed-through of nanoluciferase luminescence into the green channel.

3.5 | Luminescence imaging NLuc- β_2 ARs in CRISPR/Cas9 genome-edited HEK293 T cells under endogenous promotion

In HEK293 T cells, the endogenous expression of β_2 -adrenoceptors is extremely low, and we have previously shown that β_2 ARs tagged with an N-terminal SNAP label under endogenous promotion are not detectable by standard confocal microscopy in CRISPR/Cas9 genome-edited HEK293 T cells (Figure S4).³⁵ To confirm this low level of expression, we used CRISPR/Cas9 genome editing to incorporate an N-terminal NLuc tag to the β_2 AR under endogenous promotion as we have described previously.³² Quantification of NLuc- β_2 AR expression, as measured on the PHERAstar FS plate reader, showed a 20.1-fold higher expression of β_2 ARs in the exogenous stable cell line compared to the genome-edited HEK293 T cells (Figure 6A). Interestingly, the NLuc- β_2 AR was clearly detectable in the genome-edited cells using bioluminescence imaging microscopy (Figure 6B). The signal to noise ratio is much greater for bioluminescence imaging compared to standard confocal imaging and as such imaging at




FIGURE 4 Confocal imaging of fluorescent ICI 118,551 derivatives on HEK293 T cells expressing the SNAP- β_2 AR. Cells were incubated in fluorescent ligand (100 nM) 9c (A-D), 12a (E-H), 8c (I-L), and 9a (M-P) following 30 min incubation in the presence or absence of 10 μ M propranolol. Fluorescent localization of the β_2 AR (C, G, K, O) matches that illustrated by the SNAP-tagged dye (A, E, I, M) and is prevented from binding after propranolol addition (D, H, L, P). Similar data were obtained in three further experiments

endogenous levels is possible. It must be noted, however, that a longer exposure time (1 min) was required to image the CRISPR/Cas9 genome-edited NLuc- β_2 AR than the transfected cell lines (5 sec, Figure 6B-E).

3.6 | NanoBRET binding of 9c and 12a to CRISPR/Cas9 genome-edited NLuc- β_2 ARs under endogenous promotion in HEK293 T cells

The huge dynamic range (brightness) of the nanoluciferase luminescence allowed NanoBRET ligand binding of both 9c and 12a to be monitored in genome-edited HEK293 T cells. The PEG-BODIPY-X-630/650 analog of ICI 118,551 (12a) showed clear saturable binding with a pK_D value of 7.84 ± 0.17 ($n = 7$; Figure 7A), which was similar to the 7.56 ± 0.08 ($n = 5$) determined for 12a in the transgenic cell line (Table 1). The level of non-specific binding (obtained in the presence of 10 μ M propranolol) was, however, extremely low (Figure 7A). Competition binding experiments in this cell line with 12a showed the expected β_2 -selectivity with propranolol (pKi 9.78 ± 0.21 ; $n = 5$) and salmeterol (8.76 ± 0.21 ; $n = 5$), and ICI 118,551 (9.70 ± 0.22 ; $n = 5$) showing high affinity and the β_1 -selective antagonist CGP 20712A a very low affinity (Figure 7B). Similarly, the β Ala- β Ala-BODIPY-FL-X analog of ICI 118,551 (9c) also showed clear saturable binding to NLuc- β_2 ARs in genome-edited HEK293 T cells (Figure 8A) with a pK_D 7.71 ± 0.14 ($n = 6$) that was similar to that measured in transgenic HEK293 T cells (7.48 ± 0.08 ; Table 1), although the level of non-specific binding appeared higher than observed with the red ligand (Figure 8A). This is likely to be due to

bleed-through of nanoluciferase luminescence into the green channel (509/22 nm). Competition binding experiments in this cell line with 9c also showed the expected β_2 -selectivity with propranolol (pKi 9.55 ± 0.22 ; $n = 7$) and salmeterol (pKi 8.98 ± 0.27 ; $n = 6$), and ICI 118,551 (9.69 ± 0.22 ; $n = 7$) showing high affinity and the β_1 -selective antagonist CGP 20712A a much lower affinity (6.46 ± 0.12 ; $n = 4$; Figure 8B).

Finally, we investigated whether NanoBRET ligand binding could be visualized in CRISPR/Cas9 genome-edited cells using luminescence microscopy. Clear specific binding was detectable with both 12a and 9c in these cells (Figure 9), although, as might be expected, the exposure time for both ligands needed to be extended to allow detection. Nevertheless, significant displacement of specific binding by propranolol was detected in paired experiments (Figure 9).

4 | DISCUSSION

Until recently, the use of NanoBRET to investigate ligand-binding properties required the exogenous expression of the nanoluciferase-tagged GPCR of interest, and this can affect how receptors interact and signal. For example, the CXCR4 chemokine receptor has recently been shown to transiently form homodimers at high receptor densities.⁴⁶ β_2 ARs are also known to have a propensity to form dimers and higher order oligomers.⁴⁷ To maintain the normal cellular context, we have recently used CRISPR/Cas9-mediated homology-directed repair to insert both luminescent and fluorescent tags onto the N-terminus of GPCRs into the endogenous genome, where their expression is




FIGURE 5 NanoBRET imaging of fluorescent ICI 118,551 derivatives. Cells were incubated with fluorescent ligand (100 nM) **12a** (A-D), **9a** (E-H), and **9c** (I-L) in the absence or presence of 10 μ M propranolol before addition of furimazine (5 μ M) and imaging. Filtered bioluminescence was captured using a 438/24 band-pass filter. BRET was captured using a 650/50 nm band-pass filter or a 509/22 nm band-pass filter. Mean corrected BRET ratios in the absence (filled circle) or presence (open circle) of propranolol (P; 10 μ M) from four separate experiments are illustrated for **12a** (M) and **9a** (N) and from five separate experiments for **9c** (O). Corrected BRET ratios were significantly reduced in the presence of propranolol; paired t-test * $P < .05$. Grouped average \pm S.E.M. is displayed. Scale bar represents 50 μ m

regulated by endogenous promoters.^{30-32,35} In the present manuscript, we have investigated the utility of highly selective fluorescent ligands based on the β_2 AR selective antagonist ICI 118,551³³ in combination with CRISPR/Cas9 genome editing to investigate ligand binding to endogenous β_2 ARs under the regulation of their native promoters in HEK293 T cells. HEK293 T cells express endogenous β_2 ARs at extremely low levels, which are not detectable by standard confocal microscopy in CRISPR/Cas9 genome-edited HEK293 T cells expressing SNAP-tag fluorescent labels [35; Figure S4].

The highly β_2 AR-selective antagonist ICI 118,551 was used as the starting point for the development of selective β_2 AR fluorescent ligands. We generated a small focused library of nine ligands based on combinations of different linkers and fluorophores. With the exception of ICI 118,551-Gly-Ala-BODIPY-FL, the remaining fluorescent ICI 118,551 analogs had good affinity ($pK_D > 7$) for the β_2 AR with good selectivity over the β_1 AR (Table 1) with the most potent and selective ligands being **8c** (ICI 118,551-Gly-Ala-BODIPY-FL-X), **9c** (ICI 118,551 β la- β Ala-BODIPY-FL-X), **12a** (ICI 118,551-PEG-BODIPY-X-630/650), and **12b** (ICI 118,551-PEG-BODIPY-FL).

9a (ICI 118,551- β Ala- β Ala-BODIPY-X-630/650) had the highest affinity at recombinant β_2 ARs (pK_D 7.57) but also exhibited significant binding affinity for the β_1 AR (pK_D 6.69). Nevertheless, among the red fluorescent ligands, **9a** had the best imaging characteristics (in terms of signal to noise and the extent of non-specific binding) in recombinant HEK293 T cells and labeling was mostly confined to the cell surface (Figure 4). In contrast, **12a** showed the highest propensity to label intracellular β_2 ARs in HEK293 T cell expressing exogenous receptor. This suggests that a combination of the PEG linker and the BODIPY-X-630/650 makes this ICI 118,551 derivative particularly susceptible to crossing the cell membrane to access the intracellular regions of the cell (to bind to intracellular β_2 ARs), or is able to stimulate to some extent receptor endocytosis. Consistent with this latter possibility, ICI 118,551 has been previously reported to stimulate MAP kinase activity via the β_2 ARs in a manner that is dependent on β -arrestin recruitment to the receptor.⁴⁸ It is also known that β_2 ARs can continue to signal from intracellular endosomes⁴⁹ and so fluorescent ligands, such as **12a**, which appear to be cell permeable and can access endosomal β_2 ARs, may have utility in unraveling the complexities of signaling from intracellular β_2 ARs.




FIGURE 6 Bioluminescence imaging of HEK293 T cells expressing NLuc- β_2 AR under endogenous promotion. (A) Relative expression of NLuc- β_2 AR in the genome-edited HEK293 T cell line compared to the exogenous HEK293 T cell line. Values are the means from five separate experiments. The lines show the overall mean and 95% confidence limits. (B-E) Cells expressing the NLuc- β_2 AR under (B) endogenous or (D) exogenous promotion were imaged on the Olympus LuminoView 200 (gain of 200) for 60 s or 5 s, respectively, and filtered bioluminescence emission (438/24 band-pass filter) collected. All other settings were kept constant. Comparative luminescence is illustrated by line profiles (50 μ m) for (C) endogenous and (E) exogenous captures. Scale bar represents 50 μ m




FIGURE 7 NanoBRET ligand binding for 12a in HEK293 T cells expressing NLuc- β_2 AR under endogenous promotion. (A) Saturation binding of 12a obtained in the absence (filled circles) and presence (open circles) of 10 μ M propranolol. Data are mean \pm S.E.M. obtained in five separate experiments. (B) Competition of 10 nM 12a in the presence of increasing concentrations of propranolol, ICI 118,551 and CGP 20712A. Data are mean \pm S.E.M. from five independent experiments

The much lower expression of β_2 ARs in native HEK293 T cells was confirmed when the luminescence detected from NLuc was compared between a stable cell line expressing exogenous NLuc- β_2 ARs under

the control of a human cytomegalovirus (CMV) promoter and CRISPR/Cas9 genome-edited NLuc- β_2 ARs under the control of their native promoters (Figure 6). This confirmed our previous observations using this




FIGURE 8 NanoBRET ligand binding for 9c on HEK293 T cells expressing NLuc- β_2 AR under endogenous promotion. (A) Saturation binding of 9c was obtained in the absence (filled circles) and presence (open circles) of 10 μ M propranolol. Data are mean \pm S.E.M obtained in six separate experiments. (B) Competition of 10 nM 9c in the presence of increasing concentrations of propranolol, ICI 118,551, and CGP 20712A. Data are mean \pm S.E.M. from four (CGP 20712A) or seven (propranolol, ICI 118,551) independent experiments




FIGURE 9 NanoBRET imaging of β_2 AR at endogenous levels. HEK293 T cells expressing NLuc- β_2 AR under endogenous promotion were incubated with fluorescent ligand (100 nM) 12a (A-D) or 9c (E-H) in the absence or presence of 10 μ M propranolol before addition of furimazine (5 μ M) and imaging. Filtered bioluminescence was captured using a 438/24 band-pass filter, BRET was captured using a 650/50 nm band-pass filter or a 509/22 nm band-pass filter. Mean corrected BRET ratios in the absence or presence of propranolol (P; 10 μ M) from five separate experiments are illustrated for 12a (I) and 9c (J). Corrected BRET ratios were significantly reduced in the presence of propranolol; paired t-test * P < .05. Paired experiments are connected by line. Scale bar represents 50 μ m

approach with CXCR4 chemokine receptors.³¹ Nevertheless, even at this low expression level in the CRISPR genome-edited cells, we were able to visualize the expression of NLuc- β_2 ARs using real-time luminescence microscopy in a manner which was not possible using conventional confocal microscopy of a similar genome-editing approach to insert a SNAP-based fluorescent tag onto the native β_2 ARs.³⁵ This shows the huge advantage of using the very bright nanoluciferase and the ability to capitalize on its large dynamic range⁵⁰ to visualize NLuc-tagged receptors at very low expression levels.

The combination of highly β_2 AR-selective fluorescent ligands and genome-edited cells expressing NLuc- β_2 ARs under the control of

their native promoters has enabled real-time NanoBRET ligand binding to be performed on these receptors for the first time. The high β_2 AR-selectivity removes any complications caused by the potential of the fluorescent ligand binding to endogenous β_1 ARs and mediating a BRET signal via bystander resonance energy transfer. Furthermore, the ligand-binding properties in terms of competition by selective β_2 - and β_1 - ligands in CRISPR/Cas9-edited cells were very similar to those obtained for the transgenic cell line. The pK_D values obtained for both 12a (ICI 118,551-PEG-BODIPY-X-630/650) and the green ligand 9c (ICI 118,551 β Ala- β Ala-BODIPY-FL-X) were similar to the values obtained with the same fluorescent ligand in the transgenic cell line.

5 | CONCLUSION

In summary, the present manuscript has generated some high β_2 AR-selective fluorescent ligands based on ICI 118,551 that have been used to investigate ligand binding to β_2 ARs in CRISPR/Cas9 genome-edited HEK293 T cells where the endogenous receptor expression is extremely low. We have used these ligands to undertake for the first time real-time ligand binding to the native β_2 ARs to provide both quantitative data on ligand-binding characteristics and to allow visualization of the ligand-binding interactions using NanoBRET luminescence imaging. The fluorescent ligands studied have different abilities to label intracellular β_2 ARs and these should be valuable tools to help unravel the complexities of β_2 AR pharmacology in endosomal compartments where these receptors can continue to signal after agonist-induced receptor endocytosis.

ETHICS APPROVAL STATEMENT

No ethical approvals were required for this work.

ACKNOWLEDGEMENTS

This work was supported by the Medical Research Council (grant number MR/N020081/1). We thank Dr Leigh Stoddart for discussion and critical appraisal of this manuscript.

DISCLOSURE

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

Participated in research design: JG, SJM, MS, SJB, CWW, BK, SJH. Conducted experiments: JG, SJM, MS, CWW. Performed data analysis: JG, MS, CWW. Wrote or contributed to the writing of the manuscript: JG, SJM, MS, JW, SJB, CWW, BK, SJH.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Joëlle Goulding  <https://orcid.org/0000-0002-6227-4483>

Sarah J. Mistry  <https://orcid.org/0000-0003-1409-0097>

Mark Soave  <https://orcid.org/0000-0002-9199-1772>

Jeanette Woolard  <https://orcid.org/0000-0001-5406-6847>

Carl W. White  <https://orcid.org/0000-0002-4975-6189>

Barrie Kellam  <https://orcid.org/0000-0003-0030-9908>

Stephen J. Hill  <https://orcid.org/0000-0002-4424-239X>

REFERENCES

- Bylund DB, Eikenberg DC, Hieble JP, et al. International Union of Pharmacology nomenclature of adrenoceptors. *Pharmacol Rev.* 1994;46:121-136.
- Matera MG, Page CP, Calzetta L, Rogliani P, Cazzola M. Pharmacology and therapeutics of bronchodilators revisited. *Pharmacol Rev.* 2020;72:218-252.
- Johnson M. The β -Adrenoceptor. *Am J Respir Crit Care Med.* 1998;158(supplement 2):S146-S153.
- Madamanchi A. Beta-adrenergic receptor signaling in cardiac function and heart failure. *Mcgill J Med.* 2007;10:99-104.
- Tanaka Y, Horinouchi T, Koike K. New insights into β -Adrenoceptors in smooth muscle: distribution of receptor subtypes and molecular mechanisms triggering muscle relaxation: β -Adrenoceptors and smooth muscle relaxation. *Clin Exp Pharmacol Physiol.* 2005;32:503-514.
- Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure. *J Am College of Cardiology.* 2009;54:1747-1762.
- Xiao RP. Beta-adrenergic signaling in the heart: dual coupling of the beta2-adrenergic receptor to G(s) and G(i) proteins. *Sci STKE.* 2001;2001(104):re15.
- Strohman MJ, Maeda S, Hilger D, Masureel M, Du Y, Kobilka BK. Local membrane charge regulates β_2 adrenergic receptor coupling to Gi3. *Nat Commun.* 2019;10:2234.
- Matera MG, Calzetta L, Puxeddu E, Rogliani P, Cazzola M. A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. *Expert Opin Drug Saf.* 2018;17:509-517.
- Gauthier C, Tavernier G, Charpentier F, Langin D, Le Marec H. Functional beta3-adrenoceptor in the human heart. *J Clin Invest.* 1996;98:556-562.
- Krief S, Lönnqvist F, Raimbault S, et al. Tissue distribution of beta 3-adrenergic receptor mRNA in man. *J Clin Invest.* 1993;91:344-349.
- Thomas RF, Liggett SB. Lack of beta 3-adrenergic receptor mRNA expression in adipose and other metabolic tissues in the adult human. *Mol Pharmacol.* 1993;43:343-348.
- Staus DP, Strachan RT, Manglik A, et al. Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation. *Nature.* 2016;535:448-452.
- Ring AM, Manglik A, Kruse AC, et al. Adrenaline-activated structure of β_2 -adrenoceptor stabilized by an engineered nanobody. *Nature.* 2013;502:575-579.
- Rosenbaum DM, Zhang C, Lyons JA, et al. Structure and function of an irreversible agonist- β_2 adrenoceptor complex. *Nature.* 2011;469:236-240.
- Masureel M, Zou Y, Picard L-P, et al. Structural insights into binding specificity, efficacy and bias of a β_2 AR partial agonist. *Nat Chem Biol.* 2018;14:1059-1066.
- Cherezov V, Rosenbaum DM, Hanson MA, et al. High-resolution crystal structure of an engineered human 2-adrenergic G protein-coupled receptor. *Science.* 2007;318:1258-1265.
- Stoddart LA, Kilpatrick LE, Hill SJ. NanoBRET approaches to study ligand binding to GPCRs and RTKs. *Trends Pharmacol Sci.* 2018;39:136-147.
- Soave M, Briddon SJ, Hill SJ, Stoddart LA. Fluorescent ligands: Bringing light to emerging GPCR paradigms. *Br J Pharmacol.* 2020;177:978-991.
- Sykes DA, Stoddart LA, Kilpatrick LE, Hill SJ. Binding kinetics of ligands acting at GPCRs. *Mol Cell Endocrinol.* 2019;485:9-19.
- Stoddart LA, White CW, Nguyen K, Hill SJ, Pflieger KDG. Fluorescence- and bioluminescence-based approaches to study GPCR ligand binding: fluorescence and bioluminescence in ligand binding. *Br J Pharmacol.* 2016;173:3028-3037.
- Stoddart LA, Vernall AJ, Bouzo-Lorenzo M, et al. Development of novel fluorescent histamine H1-receptor antagonists to study ligand-binding kinetics in living cells. *Sci Rep.* 2018;8:1572.
- Conroy S, Kindon ND, Glenn J, et al. Synthesis and evaluation of the first fluorescent antagonists of the human P2Y2 receptor based on AR-C118925. *J Med Chem.* 2018;61:3089-3113.
- Comeo E, Kindon ND, Soave M, et al. Subtype-selective fluorescent ligands as pharmacological research tools for the human adenosine A2A receptor. *J Med Chem.* 2020;63:2656-2672.
- Vernall AJ, Stoddart LA, Briddon SJ, Hill SJ, Kellam B. Highly potent and selective fluorescent antagonists of the human adenosine A3

- receptor based on the 1,2,4-Triazolo[4,3-*a*]quinoxalin-1-one scaffold. *J Med Chem.* 2012;55:1771-1782.
26. Mitronova GY, Lukinavičius G, Butkevich AN, et al. High-affinity functional fluorescent ligands for human β -adrenoceptors. *Sci Rep.* 2017;7:12319.
 27. Baker JG, Adams LA, Salchow K, et al. Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β -adrenoceptors. *J Med Chem.* 2011;54:6874-6887.
 28. Kaskova ZM, Tsarkova AS, Yampolsky IV. 1001 lights: Luciferins, luciferases, their mechanisms of action and applications in chemical analysis, biology and medicine. *Chem Soc Rev.* 2016;45:6048-6077.
 29. Stoddart LA, Johnstone EKM, Wheal AJ, et al. Application of BRET to monitor ligand binding to GPCRs. *Nat Methods.* 2015;12:661-663.
 30. White CW, Johnstone EKM, See HB, Pflieger KDG. NanoBRET ligand binding at a GPCR under endogenous promotion facilitated by CRISPR/Cas9 genome editing. *Cell Signal.* 2019;54:27-34.
 31. White CW, Caspar B, Vanyai HK, Pflieger KDG, Hill SJ. CRISPR-mediated protein tagging with nanoluciferase to Investigate native chemokine receptor function and conformational changes. *Cell Chem Biol.* 2020;27(499-510):e7.
 32. Kilpatrick LE, Alcobia DC, White CW, et al. Complex formation between VEGFR2 and the β 2-Adrenoceptor. *Cell Chem Biol.* 2019;26(830-41):e9.
 33. Bilski AJ, Halliday SE, Fitzgerald JD, Wale JL. The pharmacology of a β 2-selective adrenoceptor antagonist (ICI 118,551). *J Cardiovasc Pharmacol.* 1983;5:430-437.
 34. Soave M, Stoddart LA, Brown A, Woolard J, Hill SJ. Use of a new proximity assay (NanoBRET) to investigate the ligand-binding characteristics of three fluorescent ligands to the human β 1-adrenoceptor expressed in HEK-293 cells. *Pharmacol Res Perspect.* 2016;4:e00250.
 35. Goulding J, Kondrashov A, Mistry SJ, et al. The use of fluorescence correlation spectroscopy to monitor cell surface β 2-adrenoceptors at low expression levels in human embryonic stem cell-derived cardiomyocytes and fibroblasts. *FASEB J.* 2021;35(4). in press.
 36. Baker JG. The selectivity of β -adrenoceptor antagonists at the human β 1, β 2 and β 3 adrenoceptors: β -Blockers and β -adrenoceptor selectivity. *Br J Pharmacol.* 2005;144:317-322.
 37. Balaji J, Ryan TA. Single-vesicle imaging reveals that synaptic vesicle exocytosis and endocytosis are coupled by a single stochastic mode. *Proc Natl Acad Sci U S A.* 2007;104:20576-20581.
 38. Harding SD, Sharman JL, Faccenda E, et al. updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. *Nucleic Acids Res.* 2019;2018(46):D1091-1106.
 39. Alexander SPH, Christopoulos A, Davenport AP, et al. The concise guide to pharmacology 2019/20: G protein-coupled receptors. *Br J Pharmacol.* 2019;176(Suppl 1) S21-S141.
 40. Wacker D, Fenalti G, Brown MA, et al. Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. *J Am Chem Soc.* 2010;132:11443-11445.
 41. Alcobia DC, Ziegler AI, Kondrashov A, et al. Visualizing Ligand Binding to a GPCR In Vivo Using NanoBRET. *iScience.* 2018;6:280-288.
 42. Vernal AJ, Stoddart LA, Briddon SJ, et al. Conversion of a non-selective adenosine receptor antagonist into A3-selective high affinity fluorescent probes using peptide-based linkers. *Org Biomol Chem.* 2013;11:5673.
 43. Baker JG, Middleton R, Adams L, et al. Influence of fluorophore and linker composition on the pharmacology of fluorescent adenosine A1 receptor ligands: Fluorescent A1 receptor ligands. *Br J Pharmacol.* 2010;159:772-786.
 44. Baker JG. The selectivity of β -adrenoceptor agonists at human β 1-, β 2- and β 3-adrenoceptors: β -Adrenoceptor agonist selectivity. *Br J Pharmacol.* 2010;160:1048-1061.
 45. Briddon SJ, Kellam B, Hill SJ. Design and use of fluorescent ligands to study ligand-receptor interactions in single living cells. *Methods Mol Biol.* 2011;746:211-236.
 46. İşbilir A, Möller J, Arimont M, et al. Advanced fluorescence microscopy reveals disruption of dynamic CXCR4 dimerization by subpocket-specific inverse agonists. *Proc Natl Acad Sci U S A.* 2020;117:29144-29154.
 47. Calebiro D, Rieken F, Wagner J, et al. Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization. *Proc Natl Acad Sci U S A.* 2013;110:743-748.
 48. Azzi M, Charest PG, Angers S, et al. Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. *Proc Natl Acad Sci U S A.* 2003;100:11406-11411.
 49. Irannejad R, Tomshine JC, Tomshine JR, et al. Conformational biosensors reveal GPCR signalling from endosomes. *Nature.* 2013;495:534-538.
 50. Hall MP, Unch J, Binkowski BF, et al. Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. *ACS Chem Biol.* 2012;7:1848-1857.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Goulding J, Mistry SJ, Soave M, et al. Subtype selective fluorescent ligands based on ICI 118,551 to study the human β 2-adrenoceptor in CRISPR/Cas9 genome-edited HEK293T cells at low expression levels. *Pharmacol Res Perspect.* 2021;9:e00779. <https://doi.org/10.1002/prp2.779>